Gabatarwa
A cikin 'yan shekarun nan, tattaunawar duniya game da kula da nauyi da maganin kiba ya canza sosai. Kimiyyar likitanci ta kasance tana tura iyakoki na abin da zai yiwu, wucewa fiye da shawarar salon rayuwa da magunguna na yau da kullun zuwa ci gaba, hanyoyin warkewa masu yawa. Ɗaya daga cikin abubuwan da aka fi magana game da ci gaba shine Retatrutid -maganin asarar nauyi mai zuwa na gaba a halin yanzu a cikin binciken asibiti. Ba kamar jiyya na baya ba, Retatrutid yana aiki ta hanyar sabon tsarin da ke niyya ga masu karɓar hormone da yawa, yana ba da alƙawarin ba kawai don rage nauyi ba har ma don inganta lafiyar rayuwa. Wannan labarin yana ba da cikakken jagora mai zurfi zuwa Retatrutid , yana rufe yadda yake aiki, amfaninsa, sakamako masu illa, shaidar asibiti, da kuma yiwuwar gaba a cikin kiba da kula da ciwon sukari.
Menene Retatrutid? Bayanin Bayani
Retatrutid magani ne na gwaji wanda Eli Lilly ya ƙera wanda ke cikin sabon nau'in hanyoyin kwantar da hankali da yawa. Ba kamar magungunan hanya ɗaya ba kamar semaglutide (GLP-1 agonist), Retatrutid yana kunna masu karɓa daban-daban guda uku a lokaci guda :
GLP-1 (Glucagon-kamar peptide-1) - yana inganta satiety, yana jinkirin zubar ciki, kuma yana tallafawa tsarin sukari na jini.
GIP (Glucose-dogara insulinotropic polypeptide) - yana haɓaka haɓakar insulin kuma yana taimakawa daidaita metabolism na mai.
Mai karɓar Glucagon - yana ƙara yawan kashe kuzari kuma yana tallafawa rushewar mai.
An ƙera wannan tsarin 'Agongon sau uku' don ƙirƙirar tasirin haɗin gwiwa akan rage nauyi, sarrafa ci, da haɓakar rayuwa. Bayanan gwaji na asibiti na farko sun nuna cewa Retatrutid zai iya haifar da sakamakon asarar nauyi wanda ya zarce magungunan da aka yarda da su a halin yanzu.
Yadda Retatrutid ke Aiki: Kimiyyar Bayan Magungunan
Retatrutid ya fito fili saboda yana kwaikwayi kuma yana haɓaka tasirin abubuwan da ke faruwa ta dabi'a da ke tattare da yunwa da daidaiton kuzari. Ga yadda yake aiki a jiki:
Kunna GLP-1 : Yana rage sha'awar ci ta siginar cikawa ga kwakwalwa, yana rage zubar ciki, kuma yana daidaita sukarin jini.
Kunna GIP : Yana aiki tare da GLP-1 don ƙarin sarrafa ci, haɓaka haɓakar insulin, da ƙarfafa haɓakar mai.
Kunna Glucagon : Yana haɓaka ƙona calories mafi girma ta hanyar motsa jiki don sakin kuzarin da aka adana da haɓaka ƙimar rayuwa.
Haɗin tasirin shine ƙarancin cin abinci, ƙona calories mafi girma, da ingantaccen sarrafa glucose - mai ƙarfi uku ga daidaikun mutane masu fama da kiba da yanayin rayuwa mai alaƙa. Tasirin
| Hanyar Hormone |
Ayyukan Farko na |
a cikin Retatrutid |
| GLP-1 |
Gamsuwa, jinkirin narkewa, sarrafa sukarin jini |
Yana rage ci, yana daidaita glucose |
| GIP |
Insulin saki, mai metabolism |
Yana haɓaka haɓakar insulin, amfani da mai |
| Glucagon |
Kudin makamashi, sakin glucose |
Yana haɓaka ƙona kalori, yana tattara shagunan mai |
Gwajin asibiti da Shaida akan Retatrutid
Ya zuwa yanzu, Retatrutid ya yi gwajin gwaji na asibiti na Phase 2 , tare da sakamakon da ke haifar da gagarumin farin ciki a cikin al'ummar likitanci. A cikin binciken da ya shafi manya da kiba, Retatrutid ya nuna:
Matsakaicin asarar nauyi fiye da 20% na nauyin jiki a wasu mahalarta bayan makonni 48.
Babban sakamako idan aka kwatanta da magungunan GLP-1 na yanzu kamar semaglutide.
Haɓakawa a cikin alamomin rayuwa, gami da sukarin jini, cholesterol, da hawan jini.
Wannan matakin rage nauyi ba a taɓa yin irinsa ba a cikin jiyya na harhada magunguna kuma yana fuskantar sakamakon da aka saba gani tare da tiyatar bariatric, amma ba tare da haɗarin haɗari ba.
Wani sanannen binciken shi ne cewa Retatrutid ya bayyana tasiri a cikin ƙungiyoyin marasa lafiya daban-daban, gami da waɗanda ke da nau'in ciwon sukari na 2-yankin da wasu magungunan asarar nauyi suka rasa tasiri.
Fa'idodin Retatrutid Idan aka kwatanta da Abubuwan Jiyya na yanzu
Don fahimtar yiwuwar Retatrutid, yana taimakawa wajen kwatanta shi da wasu sanannun kwayoyi kamar semaglutide (Wegovy, Ozempic) da tirzepatide (Mounjaro).
| Feature |
Semaglutid |
Tirzepatid |
Retatrutid |
| Manufofin Mai karɓa |
GLP-1 |
GLP-1 + GIP |
GLP-1 + GIP + Glucagon |
| Matsakaicin Rage Nauyi |
10-15% |
15-20% |
Har zuwa 24% (gwaji na farko) |
| Tasirin Sugar Jini |
Mai ƙarfi |
Mai Qarfi |
Mai Qarfi |
| Tasirin Metabolic |
Matsakaici |
Babban |
Mai Girma |
Abubuwan da ake iya amfani da su na Retatrutid sun haɗa da:
Babban Rage Nauyi - Matsakaicin asarar nauyi fiye da magungunan yanzu.
Amfanin Metabolic - Kyakkyawan tasiri akan lafiyar zuciya da jijiyoyin jini da juriya na insulin.
Mai yuwuwar Yin jinkirin tiyata - Zai iya samar da madadin ga marasa lafiya da ke la'akari da tiyatar bariatric.
Matsalolin Dabaru masu yuwuwa da Bayanan Tsaro na Retatrutid
Kamar duk magunguna, Retatrutid ya zo tare da yiwuwar sakamako masu illa, mafi yawan abin da ke da alaƙa da tasirinsa akan narkewa da metabolism. Abubuwan da aka ruwaito a cikin gwaje-gwajen asibiti sun haɗa da:
Tashin zuciya, amai, da gudawa - Kama da sauran magungunan GLP-1, kamar yadda jiki ya dace da rage narkewar abinci.
Ciwon kai - Duk da yake yana da amfani ga asarar nauyi, wasu marasa lafiya na iya samun raguwar rashin jin daɗi.
Ƙananan rashin jin daɗi na ciki - Yawancin lokaci na ɗan lokaci kuma yana raguwa tare da ci gaba da amfani.
Ya zuwa yanzu, babu wasu manyan abubuwan da suka shafi tsaro kamar su hypoglycemia mai tsanani ko al'amurran da suka shafi zuciya da jijiyoyin jini da aka ruwaito a cikin gwaji, amma ana buƙatar babban karatun Mataki na 3 don tabbatar da aminci na dogon lokaci.
Wanene zai iya amfana da yawa daga Retatrutid?
Har yanzu Retatrutid bai samuwa a kasuwanci ba, amma bisa ga bayanan gwaji, mutanen da za su iya amfana sun haɗa da:
Mutanen da ke da kiba masu jure canjin rayuwa.
Marasa lafiya da nau'in ciwon sukari na 2 da kiba , suna buƙatar asarar nauyi da sarrafa glucose.
Mutanen da ke cikin haɗarin cututtukan zuciya da jijiyoyin jini , waɗanda zasu iya amfana daga haɓakar cholesterol da hawan jini.
Wannan matsayi na Retatrutid a matsayin mai iya canza wasa ga marasa lafiya waɗanda suka gwada wasu hanyoyin kwantar da hankali tare da iyakacin nasara.
Makomar Retatrutid a Gudanar da Weight
Ya zuwa yanzu, Retatrutid har yanzu yana cikin lokacin gwaji na asibiti, kuma kasancewar sa ya dogara da nasarar kammala gwajin lokaci na 3 da kuma amincewar tsari. Masana sun yi imanin cewa idan an amince da shi, zai iya:
Sake ƙayyadaddun ƙa'idodin maganin kiba.
Gasa kai tsaye tare da tiyatar bariatric dangane da inganci.
Bude sabon bincike a cikin hanyoyin kwantar da hankali masu yawa don rikice-rikice na rayuwa.
Ga marasa lafiya da masu ba da kiwon lafiya, jin daɗin da ke kewaye da Retatrutid ba kawai game da wani zaɓi na asarar nauyi ba ne - game da yuwuwar sabon zamani a cikin maganin kiba inda magunguna ke ba da canji, sakamako mai dorewa.
Kammalawa
Retatrutid yana wakiltar ɗayan mafi kyawun ci gaba a cikin kiba da jiyya na cututtukan rayuwa. Ta hanyar niyya GLP-1, GIP, da masu karɓar glucagon lokaci guda, ya nuna yuwuwar asarar nauyi da ba a taɓa gani ba, ingantaccen sarrafa glucose, da haɓaka lafiyar rayuwa . Duk da yake har yanzu ana kan bincike kuma har yanzu ba a amince da shi don amfanin jama'a ba, sakamakon asibiti ya zuwa yanzu yana nuna zai iya zama ma'aunin zinare na gaba a cikin kula da kiba. Ga miliyoyin duniya waɗanda ke gwagwarmaya tare da sarrafa nauyi, Retatrutid na iya zama ci gaba wanda ke canza rayuwa.
FAQ
1. Ta yaya Retatrutid ya kwatanta da Ozempic ko Wegovy?
Retatrutid ya kai hari kan hanyoyin hormone guda uku maimakon ɗaya, kuma binciken farko ya nuna yana iya haifar da asarar nauyi fiye da semaglutide (Ozempic/Wegovy).
2. Wane irin asarar nauyi marasa lafiya zasu iya tsammanin tare da Retatrutid?
A cikin gwaje-gwajen asibiti, wasu mahalarta sun rasa fiye da kashi 20% na nauyin jikinsu-sakamakon kwatankwacin tiyatar bariatric.
3. Shin illar Retatrutid mai tsanani ne?
Yawancin illolin da aka ruwaito ya zuwa yanzu sune gastrointestinal ( tashin zuciya, zawo, amai) kuma suna da kyau a kan lokaci.
